1420478-88-1

Basic information

• Product Name: 1-Pyrrolidinecarboxylic acid, 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-, phenylmethyl ester, (2S)-
• Synonyms: 1-Pyrrolidinecarboxylic acid, 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-, phenylmethyl ester, (2S)-;benzyl (S)-2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate;(S)-benzyl 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate;benzyl (2S)-2-{8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl}pyrrolidine-1-carboxylate;S)-2-(8-Amino-1-bromo-imidazo[1,5-a]pyrazin-3-yl)-pyrrolidine -1-carboxylic acid benzyl ester;(2S)-2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-1-Pyrrolidinecarboxylic acid phenylmethyl ester;EOS-60755;1-Pyrrolidinecarboxylic acid, 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-, phenylmethyl ester,
• CAS NO: 1420478-88-1
• Molecular Formula: C₁₈H₁₈BrN₅O₂
• Molecular Weight: 416.27182
• EINECS: 1312995-182-4
• Mol File: 1420478-88-1.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• Density: 1 +-.0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 4.67±0.30(Predicted)
• CAS DataBase Reference: 1-Pyrrolidinecarboxylic acid, 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-, phenylmethyl ester, (2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxylic acid, 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-, phenylmethyl ester, (2S)-(1420478-88-1)
• EPA Substance Registry System: 1-Pyrrolidinecarboxylic acid, 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-, phenylmethyl ester, (2S)-(1420478-88-1)

Safety Data

• Hazardous Substances Data: 1420478-88-1(Hazardous Substances Data)

Usage

Uses

(2S)-2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-1-Pyrrolidinecarboxylic acid phenylmethyl ester is used to Acalabrutinib intermediate.

Synthesis

Compound 4b (46.33 g, 100 mmol) and toluene (463 mL) were added to a three-neck flask.After stirring uniformly, trifluoroacetic acid (18.02 g, 300 mmol) was slowly added.Heat to 75-80 ° C for 6-8 hours.The raw materials disappeared and then cooled to room temperature.Wash with 5% sodium hydroxide solution (463 mL).Washed once with saturated saline (231 mL),Dry over sodium sulfate, filter,The filtrate was added with ammonium acetate (38.54 g, 500 mmol).Heating and refluxing for 10 to 16 hours,The reaction was cooled to room temperature.Add water (463 mL),Dispensing after stirring,The aqueous phase was extracted once more with toluene,The combined organic phases were washed with saturated brine (231 mL).Dry with sodium sulfate,Concentrated to remove the solvent,Isopropanol petroleum ether mixed solvent recrystallized,Filter, dryCompound 6b (31.64 g, 2 steps 76%) was dried.

Upstream product

• 1333433-59-2 (S)-benzyl 2-carbamimidoylpyrrolidine-1-carboxylate 
• 1148-11-4 N-Benzyloxycarbonyl-L-proline 
• 1418307-17-1 benzyl (S)-2-(((3-chloropyrazin-2-yl)methyl)carbamoyl)pyrrolidine-1-carboxylate 
• 1420478-87-0 benzyl (2S)-2-(1-bromo-8-chloro-imidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate 
• 1418307-18-2 (S)-2-(8-chloroimidazo[1,5-a]pyrazin-3-yl)-1-pyrrolidinecarboxylic acid benzyl ester 
• 61350-60-5 (S)-benzyloxycarbonyl-proline acid chloride 
• 771581-15-8 (3-chloro-pyrazin-2-yl)-methylamine 
• 867165-55-7 2-((3-chloropyrazin-2-yl)methyl)isoindoline-1,3-dione 
• 95-58-9 2-chloro-3-methylpyrazine 

Downstream Products

• 1420478-90-5 4-{8-amino-3-[(2S)-pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide 
• 1420477-56-0 (S,E)-4-(8-amino-3-(1-(4-(pyrrolidin-1-yl)but-2-enoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide 
• 1420478-89-2 (S)-2-((1-(4-(pyridin-2-ylcarbamoyl)phenyl)-8-amino)imidazole[1,5-a]pyrazin-2-yl)pyrrolidine1-yl-carboxylic acid benzyl ester 
• 1420477-55-9 (S)-4-(3-(1-Acryloylpyrrolidin-2-yl)-8-aminoimidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide 
• 1420477-60-6 4-{8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide 

Relevant articles and documents

Method for preparing Acalabrutinib, in particular to method for preparing Acalabrutinib

The invention relates to the field of chemical synthesis, in particular to a chemical synthesis method for preparing Acalabrutinib. The synthesis method of the compound 3 is optimized, wherein the cyano compound 2 is reduced to obtain the compound 3 by adopting a method of generating borane in situ under the conditions of indium trichloride and sodium borohydride. The method is simple and convenient to operate, a special reaction container and hydrogen are not needed for reduction, a high-risk material catalyst nickel is prevented from being adopted, and large-scale production is facilitated.In the preparation of the compound 15, water is used as a solvent, equivalent hydrogen peroxide is added to react the compound 13 with the compound 14 to prepare the compound 15, so that the method iseconomic and environment-friendly, the post-treatment is simple and convenient, and the reaction liquid is directly subjected to centrifugal operation; in addition, the yield is high and can reach 90% or above; and the compound 15 is high in purity and does not need to be further purified, so that the technology can satisfy the requirements of industrial production.

IMIDAZOPYRIDINAMINE PHENYL DERIVATIVE AND USE THEREOF

The present invention relates to imidazopyridinamine phenyl derivatives, pharmaceutically acceptable salts and hydrates thereof, or metabolites thereof formed by any form of metabolism, and uses thereof in the preparation of medicaments for preventing and

The compounds of structure containing conjugated zincon, its pharmaceutical composition and use thereof (by machine translation)

The present invention relates to compounds having a structure containing conjugated zincon, its pharmaceutical composition and use, and in particular relates to the general formula (I) or a salt thereof to the compound represented by the, pharmaceutical compositions thereof, and its as BTK inhibitors and/or B cell activation inhibitor, for the prevention or treatment B cell activity with abnormal and/or the use of the BTK-related diseases. The compounds of lymphoma, breast cancer, liver cancer, colon cancer, gastric cancer, such as lung cancer and cervical cancer cell has better lethal effect, note has potential for the treatment of cancer and self-immune diseases related to potential. (by machine translation)